Table 1. Baseline characteristics of all patients who started treatment with PegIFN/RBV.
| Parameter* | Value | Range | n = |
| Male [%] | 65.7 | n = 617/939 | |
| Age [years] | 43.8±10.6 | 20.1–81.8 | n = 957 |
| Weight [kg] | 76.0±16.9 | 40.0–162.0 | n = 931 |
| BMI [kg/m2] | 25.0±4.8 | 15.2–57.7 | n = 919 |
| CoO Germany [%] | 60.0 | n = 538 | |
| CoO EE/USSR [%] | 30.8 | n = 276 | |
| CoO Mediterranen [%] | 6.1 | n = 55 | |
| CoO Others [%] | 3.0 | n = 27 | |
| Genotype 3 [%] | 82.7 | n = 769 | |
| HCV RNA [log10 IU/mL] | 5.8±1.0 | 1.2–8.7 | n = 934 |
| ALT [U/L] | 89.0±107.7 | 11.0–1273.0 | n = 909 |
| Cirrhosis [%] | 7.8 | n = 75/959 | |
| Steatosis [%] | 28.8 | n = 225/782 |